Skin Disorders News

Makeup not only has cosmetic applications, but medical ones too.

Vtama cream 1% has been approved in Japan for the treatment of adults with psoriasis as well as patients aged 12 years and older with atopic dermatitis, Dermavant Sciences announced in a press release.

Year-long ruxolitinib cream 1.5% treatment among children aged 2 to 11 years with extensive moderate to severe atopic dermatitis is safe, according to results presented at the Revolutionizing Atopic Dermatitis Conference.

Higher dietary sodium intake was associated with a higher risk for current atopic dermatitis, suggesting that a sodium-restricting diet may be a helpful intervention for disease management, according to a study.

Sirolimus may be a safe and effective alternative for patients with chronic spontaneous urticaria who do not respond to other treatments, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Donidalorsen trials showed positive results in treating patients with hereditary angioedema, exhibiting significant reductions in attack rates, according to a study published in The New England Journal of Medicine.

Due to medical advancements, researchers are calling for an update to the U.S. Department of Defense’s policies restricting individuals with psoriasis and atopic dermatitis from joining and remaining in the military, according to a study.

Adults treated with amlitelimab showed sustained improvement in their moderate to severe atopic dermatitis over the span of 28 weeks, Sanofi announced in a press release.

The FDA has cleared InnoCare Pharma’s investigational new drug application for ICP-332, according to a press release.

Patients with chronic spontaneous urticaria experienced early symptom improvements that were sustained through 52 weeks with remibrutinib, according to a presentation at the European Academy of Allergy & Clinical Immunology Congress.